iRhythm Technologies (IRTC)

Healthcare · Medical Devices
$106.70 +4.00% on the day Market cap $3.7B 52-week range $100.70 to $212.00 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
27% a year for 10 years

At a market value of $3.7B, iRhythm Technologies's free cash flow of $35M (fiscal 2025) would need to grow about 27% a year for the stock to be worth today's price.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from iRhythm Technologies's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price27.3% a year
Free cash flow, last – years—
Revenue, same period31.4% a year
Price to free cash flow106.9x

Fundamental grade

D

Five factors scored 1 to 9 from IRTC's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation2
Profitability2
Growth7
Financial health5
Cash efficiency4

Results from SEC filings

Fiscal years, from iRhythm Technologies's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$323M$411M$493M$592M$747M
Net income-$101M-$116M-$123M-$113M-$45M
Free cash flow-$66M-$53M-$91M-$31M$35M
EPS (diluted)-$3.46-$3.88-$4.04-$3.63-$1.39
Operating margin-31.0%-27.7%-25.4%-19.5%-7.7%

Where the revenue comes from

Revenue by products, fiscal 2025. Every breakdown, year by year.

Contracted third-party payors$392M52%
Centers for Medicare and Medicaid$179M24%
Healthcare institutions$126M17%
Non-contracted third-party payors$50M7%

Superinvestors who own IRTC

From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Ron Baron
Baron Capital (BAMCO)
Trimmed $22M0.03%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $2M0.00%Q2 2026

Insider buying

Open-market purchases by iRhythm Technologies's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of IRTC in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when IRTC trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does iRhythm Technologies's stock price imply?

At a market value of $3.7B, iRhythm Technologies would need its free cash flow to grow about 27% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price.

Are iRhythm Technologies insiders buying the stock?

No open-market insider purchases of IRTC in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own iRhythm Technologies?

2 of the superinvestors Investingly tracks hold IRTC in their latest 13F, including Ron Baron, Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.